Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

CureVac AG. (12/28/16). "Press Release: CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017". Tübingen.

Region Region San Francisco, CA
  Country United States (USA)
Organisations Organisation CureVac AG
  Group CureVac (Group)
  Organisation 2 J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 35th Annual Healthcare Conference 2017 San Francisco
  Product 2 mRNA-based vaccine
Index term Index term CureVac–JPMorgan Chase: investor conference, 201701 supply service CureVac presents at JP Morgan Healthcare Conference 2017
Persons Person Hoerr, Ingmar (CureVac 200601 CEO + co-founder)
  Person 2 Lauterbach, Verena (CureVac GmbH 201603 Senior Director Communications)

CureVac, a clinical-stage biopharma-ceutical company pioneering the field of mRNA-based technology, announced today that Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, will present at the J.P. Morgan 35th Annual Healthcare Conference 2017 to be held January 9-12, 2017, at the Westin St. Francis Hotel in San Francisco, CA.

Details of CureVac's presentation are as follows:

Event: J.P. Morgan 35th Annual Healthcare Conference 2017
Date: Wednesday, January 11, 2017
Time: 2:00 p.m. (Pacific Time)
Location: Westin St. Francis Hotel, San Francisco, CA

About CureVac AG

Founded in 2000 as a spin-off from the University of Tübingen in Germany, CureVac is a technology leader in the development of drugs that are based on the molecule Messenger RNA (mRNA). The fully integrated biopharmaceutical company has more than 15 years of expertise in handling and optimizing this versatile molecule for medical purposes and has the most advanced product pipeline and IP portfolio in the industry.

The basic principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases.

Since its inception, CureVac has received approximately $370 million (€350 million) in equity investments. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Sanofi Pasteur, the Bill & Melinda Gates Foundation and IAVI.

In 2006, CureVac successfully established the first GMP facility worldwide for the manufacturing of mRNA. In 2016 CureVac started the establishment of an industrial scale production.

For more information, please visit


Media Contacts

Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 (0) 7071 9883 1756

Andrew Mielach, Vice President
Tiberend Strategic Advisors, New York
T: +1 212 375 2694

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for CureVac (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top